List of Excipients in Branded Drug CYANOCOBALAMIN

« Back to Dashboard

Generic Drugs Containing CYANOCOBALAMIN

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	cyanocobalamin	0143-9621	BENZYL ALCOHOL
Hikma Pharmaceuticals USA Inc	cyanocobalamin	0143-9621	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	cyanocobalamin	0143-9621	WATER
Henry Schein Inc	cyanocobalamin	0404-9783	BENZYL ALCOHOL
Henry Schein Inc	cyanocobalamin	0404-9783	HYDROCHLORIC ACID
Henry Schein Inc	cyanocobalamin	0404-9783	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in CYANOCOBALAMIN?

# Of NDCs	Excipient
5	ACETIC ACID
2	BENZALKONIUM CHLORIDE
37	BENZYL ALCOHOL
2	CITRIC ACID MONOHYDRATE
2	GLYCERIN
25	HYDROCHLORIC ACID

Cyanocobalamin Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 6, 2026

Cyanocobalamin is a mature vitamin B12 active ingredient with limited protection at the molecule level and substantial competition across injections, oral products, nasal sprays, and dietary supplements. Commercial opportunity depends on delivery-system differentiation, stability, preservative strategy, pediatric acceptability, and regulatory positioning rather than new-molecule exclusivity. Injectable products remain the most regulated segment, while oral and consumer-health products offer broader formulation flexibility.

What is the regulatory status of cyanocobalamin?

Cyanocobalamin is a manufactured form of vitamin B12 used to treat or prevent vitamin B12 deficiency, including deficiency associated with pernicious anemia and malabsorption. FDA-approved drug products include parenteral cyanocobalamin injections and certain intranasal products. Many oral cyanocobalamin products are marketed as dietary supplements rather than prescription drugs.

Product category	Typical strength	Primary route	Regulatory position	Commercial profile
Cyanocobalamin injection	1,000 mcg/mL	Intramuscular or subcutaneous	Prescription drug	Mature generic market
Oral tablet or capsule	25 mcg to 5,000 mcg	Oral	Drug or dietary supplement, depending on claims and product status	Highly competitive
Sublingual or orally disintegrating product	500 mcg to 5,000 mcg	Oral transmucosal or oral	Usually supplement-led	Consumer differentiation
Nasal spray	Commonly 500 mcg per dose	Intranasal	Prescription product category	Smaller, differentiated market
Multivitamin or combination product	Variable	Oral	Drug or supplement	High-volume, low-margin

Cyanocobalamin is not a biosimilar product. It is a small-molecule vitamin and does not use the FDA biosimilar pathway under the Public Health Service Act. Generic competition is evaluated through the abbreviated new drug application pathway when an approved reference product exists.

What excipients are used in cyanocobalamin formulations?

The optimal excipient system depends on route, concentration, container closure, sterilization process, and target shelf life. Cyanocobalamin is water-soluble but sensitive to light and can be affected by oxidation, pH, trace metals, and interactions with reducing or oxidizing excipients.

Injectable formulations

A conventional cyanocobalamin injection may contain sodium chloride, sodium hydroxide or hydrochloric acid for pH adjustment, and water for injection. Some products contain sodium chloride for isotonicity. Benzyl alcohol may be used as a preservative in multidose presentations, although preservative-free packaging is preferred for neonates, infants, and certain vulnerable populations.

Key formulation controls include:

• Protection from light during manufacturing, filling, packaging, and storage.
• Control of pH, often within a mildly acidic to neutral range depending on the product.
• Low bioburden and endotoxin levels.
• Compatibility with glass vials, prefilled syringes, and elastomeric closures.
• Control of oxygen exposure and trace-metal contamination.
• Selection of a sterilization process that does not degrade the active ingredient.

A single-dose, preservative-free presentation can command a premium in hospitals and specialty clinics. Multidose vials may reduce unit cost but introduce preservative, antimicrobial effectiveness, and use-period considerations.

Oral tablets and capsules

Common oral excipients include microcrystalline cellulose, lactose, mannitol, starch, croscarmellose sodium, sodium starch glycolate, magnesium stearate, stearic acid, silicon dioxide, and film-coating polymers. The formulation target is usually rapid disintegration and acceptable content uniformity at low drug loading.

Cyanocobalamin is often present at microgram quantities. This creates a content-uniformity challenge because the active ingredient may represent a very small fraction of tablet mass. Direct blending can produce segregation and dose variability. Commercially viable approaches include:

1. Preparation of a geometric premix or ordered mixture.
2. Use of a liquid or dry granulation process.
3. Use of a carrier system with controlled particle-size distribution.
4. Manufacture of an active premix at a higher concentration before final blending.
5. In-process assay and blend-uniformity controls at multiple stages.

For high-dose supplements, the active-load problem is less severe. For 25 mcg or 50 mcg products, premix design and powder-flow control become more important than the nominal excipient cost.

Orally disintegrating and sublingual products

Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, and flavor systems are common candidates for orally disintegrating tablets. Direct compression can reduce manufacturing complexity, but hygroscopic excipients and porous tablets may require high-barrier packaging.

Sublingual products can be differentiated through:

• Fast disintegration.
• Low tablet weight.
• Mint or berry flavor masking.
• Reduced water requirement.
• Individual blister packaging.
• Improved handling for older adults with dysphagia.

Claims that imply superior absorption or bypass of gastrointestinal limitations require clinical and regulatory support. A sublingual dosage form does not automatically establish superior bioavailability.

Liquid oral formulations

Liquid cyanocobalamin products may use purified water, glycerin, sorbitol, propylene glycol, citric acid or citrate buffers, flavoring agents, sweeteners, and preservatives such as potassium sorbate or sodium benzoate. The formulation must control:

• Microbial growth.
• Sedimentation or crystallization.
• pH drift.
• Color changes caused by light exposure.
• Palatability at high vitamin concentrations.
• Dosing accuracy with oral syringes or droppers.

Sugar-free formulations using sorbitol, glycerin, or nonnutritive sweeteners offer opportunities in diabetes-focused and pediatric markets. Polyol levels must be controlled because excessive intake can cause gastrointestinal effects.

Nasal sprays

A nasal cyanocobalamin spray generally requires a buffered aqueous vehicle, tonicity adjustment, a preservative or preservative-free device, and a metered-dose pump. Excipients must support:

• Consistent delivered volume.
• Spray-pattern reproducibility.
• Appropriate viscosity.
• Nasal tolerability.
• Microbial control.
• Device compatibility.
• Stability after repeated actuation.

A preservative-free multidose nasal system can create commercial differentiation but requires a validated container-closure and microbial-control strategy. Pump geometry, plume characteristics, and priming requirements are part of the product’s performance profile and may complicate generic substitution.

What excipient strategies offer the strongest commercial opportunities?

The strongest opportunities are in differentiated presentations rather than basic cyanocobalamin tablets.

Opportunity	Excipient or technology focus	Commercial rationale
Preservative-free injection	Single-dose vial, ampoule, or prefilled syringe	Hospital safety and vulnerable-patient positioning
Pediatric liquid	Sugar-free vehicle, palatable flavor, accurate dosing device	Supports adherence and caregiver use
Orally disintegrating tablet	Mannitol, crospovidone, moisture-barrier packaging	Addresses dysphagia and convenience
High-dose oral tablet	Low-cost direct compression and robust content uniformity	Supports generic or supplement scale
Nasal spray	Buffer, isotonicity, preservative-free pump	Differentiated delivery and reduced swallowing burden
Extended-stability product	Oxygen and light-control packaging	Supports distribution and inventory flexibility
Combination product	Cyanocobalamin with folate, pyridoxine, iron, or other nutrients	Enables condition-specific positioning
Clinic-administered presentation	Prefilled syringe or ready-to-use container	Reduces preparation and administration steps

The highest-margin concepts are likely to require device, packaging, or clinical differentiation. A simple excipient substitution in a conventional tablet is unlikely to create durable pricing power.

What patents protect cyanocobalamin products?

The cyanocobalamin molecule is long off patent. Patent risk therefore centers on specific formulations, delivery systems, devices, manufacturing processes, and method-of-use claims.

IP category	Likely status	Commercial significance
Cyanocobalamin composition of matter	Expired or not commercially relevant	No meaningful molecule-level barrier
Conventional injection formulation	Generally mature and readily design-aroundable	Low patent barrier
Oral tablet excipient system	Product-specific	Usually limited unless tied to performance data
Nasal spray formulation and device	Potentially more defensible	Moderate risk depending on listing and claim scope
Prefilled syringe or delivery device	Product- and device-specific	Can delay or complicate substitution
Stability or packaging method	Narrow and implementation-dependent	Useful as secondary protection
Combination product	Depends on active ingredients and claims	May create new formulation and method claims
Manufacturing process	Potentially protectable	Relevant where purity, yield, or particle control is unusual

Patent analysis must distinguish patents from FDA Orange Book listings. A patent may exist without being listed for a product, and an Orange Book-listed patent may be challenged by an ANDA applicant through Paragraph IV certification.

What is the Orange Book status of cyanocobalamin?

The Orange Book status is product-specific, not ingredient-wide. Approved cyanocobalamin injections are generally associated with a mature abbreviated-approval environment. A nasal cyanocobalamin product may have a separate NDA history and potentially different patent and exclusivity records.

The key diligence points are:

• Whether the reference product remains active in the Orange Book.
• Whether patents are currently listed for the reference NDA.
• Whether listed patents cover the formulation, device, method of use, or packaging.
• Whether any listed patents have expired or been delisted.
• Whether an ANDA applicant has submitted a Paragraph IV certification.
• Whether pediatric, orphan, or other regulatory exclusivity applies.

No broad regulatory exclusivity should be assumed for conventional cyanocobalamin injection. Any current Orange Book conclusion must be made against the exact NDA, dosage form, strength, and marketing status recorded by FDA.

When does cyanocobalamin lose exclusivity?

Cyanocobalamin has already lost practical exclusivity as an active ingredient. Conventional injectable and oral products compete primarily on manufacturing cost, supply reliability, product quality, packaging, and channel access.

The relevant commercial timeline is therefore:

Exclusivity layer	Cyanocobalamin position
Active-ingredient patent	Long expired or commercially irrelevant
Conventional dosage-form patent	Usually expired, narrow, or product-specific
FDA new-drug exclusivity	Generally not the primary barrier for mature products
Generic substitution	Established for qualifying reference products
Device or formulation protection	May remain relevant for specific nasal or specialty products
Trademark protection	Can remain valuable even without patent protection
Manufacturing know-how	Potentially important but difficult to assess publicly

A new cyanocobalamin product can obtain regulatory exclusivity only if it qualifies under a specific approval pathway, such as a new drug application with an eligible innovation. Regulatory exclusivity would not arise merely from using a different conventional excipient.

Are there Paragraph IV challenges to cyanocobalamin products?

Paragraph IV litigation is likely to be limited for conventional cyanocobalamin injections because the market is mature and generic competition is already established. Risk is higher for a protected nasal spray, novel device, or formulation with active Orange Book-listed patents.

An ANDA applicant may certify that a listed patent is invalid, unenforceable, or will not be infringed. The reference sponsor can then file an infringement action, potentially triggering a 30-month stay of ANDA approval under the Hatch-Waxman framework. The practical value of a Paragraph IV challenge depends on:

• Remaining patent term.
• Number and quality of listed patents.
• Whether the claims cover the product or only a narrow use.
• Availability of a non-infringing formulation.
• Commercial value of the reference product.
• Expected launch timing and litigation cost.

No generic litigation conclusion should be inferred from the existence of a patent alone. The Orange Book listing, FDA approval history, and court docket must be reviewed together.

What formulation patents could protect a new cyanocobalamin product?

A commercially meaningful patent program could focus on measurable technical results. Examples include:

• A stable aqueous formulation with defined pH and impurity limits.
• A low-oxygen formulation with improved long-term potency.
• A preservative-free multidose nasal system with validated microbial control.
• A low-dose tablet with improved content uniformity.
• A fast-disintegrating tablet that maintains potency under high humidity.
• A prefilled syringe configuration with reduced adsorption or extractables.
• A combination formulation with improved chemical compatibility.
• A manufacturing process that reduces degradation products or improves yield.

Patent strength improves when claims are supported by comparative data against conventional formulations. Broad claims to cyanocobalamin plus ordinary excipients are vulnerable to obviousness challenges. Narrow claims tied to defined concentration ranges, impurity profiles, device parameters, or stability outcomes are more defensible but may be easier to design around.

How does cyanocobalamin compare with methylcobalamin?

Cyanocobalamin and methylcobalamin compete in oral supplements and combination products. Cyanocobalamin has advantages in cost, supply history, manufacturing familiarity, and regulatory precedent. Methylcobalamin is often marketed as a premium form, although marketing claims must be separated from demonstrated clinical superiority.

Attribute	Cyanocobalamin	Methylcobalamin
Cost position	Usually lower	Usually higher
Manufacturing history	Extensive	Extensive but less standardized in some markets
Consumer perception	Established, sometimes viewed as conventional	Often positioned as premium
Patent opportunity	Primarily formulation and delivery	Formulation, stability, and combination opportunities
Regulatory complexity	Mature	Product-specific
Differentiation potential	Delivery, tolerability, packaging	Form and consumer positioning

A cyanocobalamin product can compete effectively when it offers lower cost, better dosing convenience, superior taste, improved stability, or a clinically justified route of administration.

What generic entry risks exist for cyanocobalamin?

Generic entry risk is high for conventional tablets, capsules, and injections. The main barriers are operational rather than legal:

• Sterile manufacturing capacity.
• Reliable active-ingredient supply.
• Light-protective packaging.
• Low-dose content uniformity.
• Container-closure qualification.
• Extractables and leachables control.
• Stability data.
• Manufacturing-site compliance.
• Procurement contracts and wholesaler access.

For nasal sprays and prefilled devices, the risk profile changes. Device sameness, plume performance, dose delivery, priming, and human-factors requirements can increase development time and reduce the number of credible competitors.

What licensing deals and commercial partnerships are relevant?

Cyanocobalamin itself is broadly available and generally does not require an ingredient license. Partnership value is more likely in:

• Nasal delivery platforms.
• Orally disintegrating or thin-film technologies.
• Prefilled syringe and autoinjector platforms.
• Pediatric dosing devices.
• Combination-product brands.
• Contract sterile manufacturing.
• High-barrier packaging systems.
• Regional distribution and private-label supplement arrangements.

A licensing transaction is most defensible when it transfers a protected device, validated formulation platform, regulatory dossier, or manufacturing capability. A basic tablet formulation is more likely to be sourced through contract development and manufacturing than through a royalty-bearing patent license.

What is the revenue exposure and competitive landscape?

Revenue exposure varies sharply by segment. Conventional injection revenue is exposed to generic price erosion and institutional purchasing. Oral supplements have higher unit volumes but intense retail competition and low switching costs. Nasal and device-enabled products can support higher prices but address smaller patient populations and face more demanding regulatory requirements.

The principal competitors include generic injectable manufacturers, branded vitamin companies, specialty nasal-product sponsors, contract manufacturers, and private-label supplement suppliers. Competitive advantage is most likely to come from:

1. Reliable supply during injectable shortages.
2. A differentiated dosage form for patients who cannot swallow tablets.
3. Better pediatric dosing and palatability.
4. Lower total cost of administration.
5. Stronger stability and packaging performance.
6. A combination product with a clear clinical or adherence rationale.

Key Takeaways

• Cyanocobalamin has no meaningful molecule-level patent barrier.
• Conventional injections and oral products face high generic and supplement competition.
• The strongest commercial opportunities are in nasal delivery, preservative-free injectables, pediatric liquids, orally disintegrating tablets, and prefilled presentations.
• Low-dose oral products require careful premix and content-uniformity controls.
• Light, oxygen, pH, trace metals, microbial control, and container compatibility are central formulation risks.
• Patent value lies in defined formulation performance, device integration, manufacturing controls, and stability data.
• Cyanocobalamin is not subject to biosimilar regulation.
• Paragraph IV risk is generally low for mature injections but may be material for protected nasal or device products.
• Licensing opportunities are more likely to involve delivery platforms, devices, sterile manufacturing, or branded combinations than the vitamin ingredient itself.
• Product-specific Orange Book, FDA approval-history, patent, and litigation reviews are required before a launch or freedom-to-operate decision.

FAQs About Cyanocobalamin Excipient and Patent Strategy

Can benzyl alcohol be used in cyanocobalamin injection?

Benzyl alcohol can be used as a preservative in some multidose injectable products, subject to formulation, labeling, and regulatory requirements. Preservative-free presentations are preferable for neonates and certain pediatric uses.

Which excipient is best for a cyanocobalamin orally disintegrating tablet?

Mannitol is a common starting point because it supports mouthfeel and rapid dissolution. Crospovidone or low-substituted hydroxypropyl cellulose can improve disintegration, while moisture-barrier packaging is often necessary.

Does a cyanocobalamin supplement require an ANDA?

Not necessarily. A product marketed as a dietary supplement under applicable FDA requirements does not use the ANDA pathway. A product making drug claims or seeking approval as a prescription drug follows the applicable drug-approval pathway.

Can cyanocobalamin be patented through a new dosage form?

Yes, but a patent requires more than selecting a different tablet or liquid format. The strongest claims generally require a defined formulation, device, process, or demonstrated technical effect that is novel and non-obvious.

Is methylcobalamin a direct substitute for cyanocobalamin?

The two forms compete commercially but are not identical active ingredients. Substitution depends on the product’s regulatory status, labeling, dosage, clinical use, and applicable pharmacy or procurement rules.

References

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

3. U.S. Food and Drug Administration. (n.d.). Electronic Orange Book: Patent and exclusivity information. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

6. DailyMed. (n.d.). Cyanocobalamin injection prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/

7. DailyMed. (n.d.). Cyanocobalamin nasal spray prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/

8. U.S. Food and Drug Administration. (2023). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.